Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300.
The Institute for Clinical and Economic Review today released a final evidence report and report-at-a-glance assessing the comparative clinical effectiveness and value of extended-release medications for the treatment of opioid use disorder.
The report focuses on a buprenorphine implant (Probuphine, Titan), an extended-release naltrexone injection (Vivitrol, Alkermes), and two extended-release buprenorphine injections: Sublocade (Indivior) and CAM2038 (Braeburn), an investigational agent with an expected FDA approval decision later this month.
